Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

13

Revenue 2017

Bristol-Myers Squibb

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Bristol-Myers Squibb's 2013 sales performance.

Bristol-Myers Squibb

Celgene boosts IO presence with Immatics deal

Celgene boosts IO presence with Immatics deal Immatics technology promises to go beyond CAR-T capabilities. Celgene is not slowing down its strategic deals ahead of its merger with Bristol-Myers Squibb, and has strengthened its immunotherapy (IO)

Amgen snaps up Celgene’s Otezla for $13.4bn

Amgen snaps up Celgene’s Otezla for $13.4bn Higher-than-expected price helps BMS sweeten merger deal. Bristol-Myers Squibb (BMS) and Celgene look to be on track to complete their long-awaited merger after yesterday confirming the sale

AZ’s Imfinzi combo bombs again in non-small cell lung cancer

AZ’s Imfinzi combo bombs again in non-small cell lung cancer The readout will also be a concern to Bristol-Myers Squibb, which is relying on TMB data to make a case for its PD-1 inhibitor Opdivo (nivolumab) after the drug

BMS buoyed by FDA approval of Celgene’s myelofibrosis drug

BMS buoyed by FDA approval of Celgene’s myelofibrosis drug That would be good news for Bristol-Myers Squibb, which is in the throes of a  $74bn merger with Celgene.

Positive first-line phase 3 results for Tecentriq

Positive first-line phase 3 results for Tecentriq Tecentriq was the third drug to hit the growing PD-1/PD-L1 inhibitor category, with Bristol-Myers Squibb’s Opdivio and Merck &Co’s Keytruda the first to establish a

[ Previous 5 results ] 3 4 5 6 7 8 9 10 11 12 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
IGNIFI

We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...

Latest intelligence

Pharma index map
The 2019 CPhI Pharma Index Report
Examining this year’s industry performance...
Five key trends in precision and personalised healthcare
Here, we deep dive into five of the key trends in precision medicine and personalised healthcare to explore how the healthcare industry is changing and how pharmaceutical and biotech companies...
OPEN Health Graduate Programme: from OPEN VIE to OPEN Health Medical Communications
Isobel Owens shares her experience of the OPEN Health Graduate Programme from OPEN VIE to OPEN Health Medical Communications...

Infographics